Daiwa Securities Group Inc. Acquires 479 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Daiwa Securities Group Inc. lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,551 shares of the biopharmaceutical company’s stock after buying an additional 479 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,953,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ALNY. Raymond James Financial Inc. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $65,295,000. Jennison Associates LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $61,160,000. Proficio Capital Partners LLC increased its holdings in shares of Alnylam Pharmaceuticals by 25,929.6% in the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after purchasing an additional 192,916 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $41,529,000. Finally, Eventide Asset Management LLC lifted its holdings in Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after buying an additional 137,333 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research reports. Piper Sandler reissued an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Chardan Capital reiterated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a “neutral” rating in a report on Tuesday. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Stock Down 0.3 %

NASDAQ:ALNY opened at $241.75 on Friday. The stock has a 50-day simple moving average of $254.86 and a 200 day simple moving average of $260.57. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a market cap of $31.30 billion, a PE ratio of -111.41 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.